National

Growing drought, wildfires impact Canada's Q2 economy

Sep 02, 2023

Ottawa [Canada], September 2: Canada's real gross domestic product (GDP) by industry was essentially unchanged in the second quarter of 2023 after seven quarters of growth, Statistics Canada said Friday.
Growing drought and wildfires in many regions of the country contributed to lower crop production in the quarter as the yield outlook for the year declined.
Forestry and logging as well as fishing, hunting and trapping were also down in the quarter, while support activities for agriculture and forestry, which include forest firefighting activities, were up, the national statistical agency said.
Mining, quarrying, and oil and gas extraction contracted as wildfires affected activity in natural gas and crude oil extraction in Alberta in May, and iron ore mining in Quebec and Newfoundland and Labrador in June.
Accommodation services posted its first quarterly decline in the last five quarters as forest fires which began in late April in Canada, coupled with poor air quality associated with fires, restrained or indirectly discouraged activity in recreational vehicle parks and recreational camps, the agency added.
Canada's GDP decreased 0.2 percent in June and advance information indicates that real GDP was essentially unchanged in July, Statistic Canada said.
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025